WallStSmart

Novartis AG ADR (NVS)vsSHL Telemedicine Ltd American Depositary Shares (SHLT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 101248% more annual revenue ($56.69B vs $55.94M). NVS leads profitability with a 22.5% profit margin vs -15.8%. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

SHLT

Avoid

32

out of 100

Grade: F

Growth: 3.3Profit: 2.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -1.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-66.5%)

Margin of Safety

-66.5%

Fair Value

$92.73

Current Price

$153.27

$60.54 premium

UndervaluedFair: $92.73Overvalued

Intrinsic value data unavailable for SHLT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$291.32B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

SHLT1 strengths · Avg: 10.0/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Areas to Watch

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.562/10

Expensive relative to growth rate

SHLT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$39.26M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-11.5%2/10

ROE of -11.5% — below average capital efficiency

Revenue GrowthGrowth
-3.9%2/10

Revenue declined 3.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bull Case : SHLT

The strongest argument for SHLT centers on Price/Book.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Bear Case : SHLT

The primary concerns for SHLT are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

NVS profiles as a value stock while SHLT is a turnaround play — different risk/reward profiles.

NVS carries more volatility with a beta of 0.49 — expect wider price swings.

NVS is growing revenue faster at 0.8% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 32/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

SHL Telemedicine Ltd American Depositary Shares

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

SHL Telemedicine Ltd., develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company is headquartered in Tel Aviv, Israel.

Want to dig deeper into these stocks?